An economic evaluation of the SCORE2 trial indicates aflibercept treatment was unlikely to meet most accepted standards of cost-effectiveness, due to little difference in visual acuity outcomes and a large cost differential compared with bevacizumab.
Treatment for blinding blood vessel condition yields lasting vision improvement miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years.